8-K: Invivyd's VYD222 Shows Continued Antiviral Activity Against Emerging SARS-CoV-2 Variants

Invivyd announced that its monoclonal antibody, VYD222 (pemivibart), demonstrates continued in vitro neutralizing activity against the KP.1.1 FLiRT and KP.3 variants of SARS-CoV-2.

Summary

• Invivyd's VYD222 (pemivibart) has shown continued in vitro neutralizing activity against the KP.1.1 FLiRT and KP.3 variants of SARS-CoV-2.
• These variants are currently dominant, with FLiRT variants accounting for over half of circulating sequences as of June 8, 2024.
• The CDC predicts that the KP.3 variant will become the most dominant SARS-CoV-2 lineage nationally in the near term.
• VYD222's epitope has remained stable, with 99.8% of sequences submitted to GISAID in 2024 showing conservation at the binding interface.
• Invivyd's next monoclonal antibody candidate, VYD2311, also shows continued in vitro neutralization activity against these strains.
• The company uses its proprietary software, VivydTools, to monitor the SARS-CoV-2 variant landscape.

Sentiment

Score: 7

Explanation: The document presents positive data on the continued effectiveness of Invivyd's antibodies against new variants, but also acknowledges the risks and uncertainties associated with drug development and regulatory approval. The sentiment is cautiously optimistic.

Positives

• VYD222 shows continued effectiveness against new dominant variants, indicating its potential as a treatment.
• The stability of VYD222's epitope suggests it may remain effective against future variants.
• VYD2311 also shows promise in neutralizing the new variants.
• Invivyd's use of VivydTools demonstrates a proactive approach to monitoring and responding to viral evolution.

Negatives

• The results are based on in vitro pseudovirus assays, which may not fully reflect real-world effectiveness.
• VYD222 has not been approved by the U.S. FDA or any other regulatory authority.

Risks

• The effectiveness of VYD222 and VYD2311 may vary in real-world scenarios compared to in vitro assays.
• There is a risk that new variants may emerge that are not neutralized by these antibodies.
• The company's ability to obtain regulatory approval for VYD222 is not guaranteed.
• The company's future success depends on its ability to keep pace with the evolving SARS-CoV-2 virus.

Future Outlook

Invivyd will continue to monitor the SARS-CoV-2 variant landscape and assess the neutralization activity of its antibodies. The company plans to develop a series of innovative antibody candidates using its INVYMAB platform.

Management Comments

• Dr. Robert Allen, Chief Scientific Officer of Invivyd, stated that the VYD222 epitope has remained stable.
• Management is pleased with the continued demonstrated in vitro neutralization activity of VYD222 and VYD2311.

Industry Context

This announcement is relevant to the broader industry trend of developing and updating treatments for emerging viral variants. The rapid evolution of SARS-CoV-2 necessitates continuous monitoring and development of new therapies.

Comparison to Industry Standards

• The development of monoclonal antibodies to combat COVID-19 is a common strategy, with companies like Regeneron and Eli Lilly also pursuing similar approaches.
• Invivyd's focus on a platform approach (INVYMAB) to rapidly generate new antibodies is similar to other companies that are trying to stay ahead of viral mutations.
• The in vitro neutralization data is a standard initial step in assessing the potential of antibody therapies, but clinical trial data will be needed to confirm real-world efficacy.

Stakeholder Impact

• Shareholders may view the positive in vitro data as a positive development.
• The potential for effective treatments could benefit patients and healthcare providers.
• The company's employees are likely to be encouraged by the progress of their research.

Next Steps

• Invivyd will continue to monitor the SARS-CoV-2 variant landscape using VivydTools.
• The company will continue to assess the neutralization activity of VYD222 and VYD2311.
• Invivyd plans to develop a series of innovative antibody candidates.

Key Dates

Keywords

SARS-CoV-2, monoclonal antibody, VYD222, pemivibart, VYD2311, COVID-19, FLiRT variants, KP.1.1, KP.3, neutralization, antiviral, Invivyd, INVYMAB